Market News
Affamed Therapeutics Receives Approval for Phase 3 Clinical Trial of Dextenza in Mainland China for Ocular Inflammation and Pain Treatment
Affamed Therapeutics Receives Approval for Phase 3 Clinical Trial of Dextenza in Mainland China for Ocular Inflammation and Pain Treatment SHANGHAI, April 17, 2023 /PRNewswire/ — AffaMed Therapeutics Overview AffaMed Therapeutics (“AffaMed”) is a global biotechnology company that is dedicated to developing and commercializing transformative pharmaceutical, digital, and surgical products. The company focuses on addressing…
Clip Money Inc. Announces Amendment to Previously Announced Press Release: What You Need to Know!
Clip Money Inc. Announces Amendment to Previously Announced Press Release: What You Need to Know! TORONTO, April 13, 2023 (GLOBE NEWSWIRE) — Clip Money Inc. (TSX-V: CLIP) (OTCQB: CLPMF) (“Clip Money” or the “Company”), a company that operates a multi-bank self-service deposit system for businesses, is pleased to announce that it has modified the structure…